Insmed Stock Forecast, Price & News

Insmed (NASDAQ:INSM) Frequently Asked Questions

Is Insmed a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Insmed stock.
View analyst ratings for Insmed or view top-rated stocks.

How has Insmed's stock been impacted by Coronavirus (COVID-19)?

Insmed's stock was trading at $21.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INSM shares have increased by 21.8% and is now trading at $25.89.
View which stocks have been most impacted by COVID-19.

Are investors shorting Insmed?

Insmed saw a drop in short interest in the month of October. As of October 29th, there was short interest totaling 7,460,000 shares, a drop of 18.7% from the October 14th total of 9,180,000 shares. Based on an average daily trading volume, of 808,100 shares, the short-interest ratio is presently 9.2 days.
View Insmed's Short Interest.

When is Insmed's next earnings date?

Insmed is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Insmed.

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) issued its quarterly earnings results on Thursday, October, 28th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by $0.13. The biopharmaceutical company had revenue of $46.80 million for the quarter, compared to analyst estimates of $49.23 million. Insmed had a negative net margin of 243.96% and a negative trailing twelve-month return on equity of 108.34%. The business's quarterly revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.63) earnings per share.
View Insmed's earnings history.

What price target have analysts set for INSM?

6 equities research analysts have issued 1 year price targets for Insmed's shares. Their forecasts range from $48.00 to $60.00. On average, they expect Insmed's share price to reach $55.17 in the next year. This suggests a possible upside of 113.1% from the stock's current price.
View analysts' price targets for Insmed or view top-rated stocks among Wall Street analysts.

Who are Insmed's key executives?

Insmed's management team includes the following people:

• Mr. William H. Lewis J.D., Pres, CEO & Chairman (Age 50) (LinkedIn Profile)
• Mr. Paolo Tombesi, Chief Financial Officer (Age 55)
• Ms. Christine A. Pellizzari J.D., Chief Legal Officer & Corp. Sec. (Age 51)
• Mr. Roger Adsett, Chief Commercial Officer (Age 50)
• Dr. Paul D. Streck, Advisor (Age 55)

What is Will Lewis' approval rating as Insmed's CEO?

14 employees have rated Insmed CEO Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among Insmed's employees.

Who are some of Insmed's key competitors?

Some companies that are related to Insmed include Maravai LifeSciences (MRVI), Ono Pharmaceutical (OPHLF), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), United Therapeutics (UTHR), CureVac (CVAC), Ascendis Pharma A/S (ASND), Evotec (EVTCY), Jazz Pharmaceuticals (JAZZ), Grifols (GRFS), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Sarepta Therapeutics (SRPT) and Biohaven Pharmaceutical (BHVN).
View all of INSM's competitors.

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Who are Insmed's major shareholders?

Insmed's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (6.75%), William Blair Investment Management LLC (4.20%), Point72 Asset Management L.P. (3.03%), Bellevue Group AG (2.86%), Alliancebernstein L.P. (1.87%) and Geode Capital Management LLC (1.70%). Company insiders that own Insmed stock include Alfred Altomari, Christine A Pellizzari, David R Brennan, John Soriano, Melvin Md Sharoky, Orlov S Nicole Schaeffer and William Lewis.
View institutional ownership trends for Insmed.

Which major investors are selling Insmed stock?

INSM stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Barclays PLC, Ghisallo Capital Management LLC, Granahan Investment Management Inc. MA, Eagle Asset Management Inc., Neuberger Berman Group LLC, Voya Investment Management LLC, and Gyon Technologies Capital Management LP. Company insiders that have sold Insmed company stock in the last year include Alfred Altomari, Christine A Pellizzari, John Soriano, Orlov S Nicole Schaeffer, and William Lewis.
View insider buying and selling activity for Insmed or view top insider-selling stocks.

Which major investors are buying Insmed stock?

INSM stock was acquired by a variety of institutional investors in the last quarter, including Polar Capital Holdings Plc, Point72 Asset Management L.P., Suvretta Capital Management LLC, Peregrine Capital Management LLC, Bellevue Group AG, Two Sigma Advisers LP, Alliancebernstein L.P., and International Biotechnology Trust PLC.
View insider buying and selling activity for Insmed or or view top insider-buying stocks.

How do I buy shares of Insmed?

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insmed's stock price today?

One share of INSM stock can currently be purchased for approximately $25.89.

How much money does Insmed make?

Insmed has a market capitalization of $3.06 billion and generates $164.41 million in revenue each year. The biopharmaceutical company earns $-294.09 million in net income (profit) each year or ($3.92) on an earnings per share basis.

How many employees does Insmed have?

Insmed employs 373 workers across the globe.

What is Insmed's official website?

The official website for Insmed is www.insmed.com.

Where are Insmed's headquarters?

Insmed is headquartered at 700 US Highway 202/206, Bridgewater NJ, 08807.

How can I contact Insmed?

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900, via email at [email protected], or via fax at 732-438-0381.